Santiago de Cuba, Jun 23 (ACN) Starting today in the Santiago de Cuba municipality, in the homonymous province, the vaccination of phase III placebos with the anti-COVID-19 vaccine candidate Abdala, a drug with an efficacy of 92, begins 28 percent in the prevention of symptomatic disease.
Amid the national jubilation over the results that place the product developed by the Center for Genetic Engineering and Biotechnology (CIGB) among the four most effective in the world to combat the disease, hundreds of people from Santiago will reach the 11 clinical sites in the territory to receive the first dose of the immunogen.
Francisco Hernández, head of the Abdala Clinical Study, told the Cuban News Agency that since the previous week they have been in Bayamo, Guantánamo and Santiago de Cuba, towns where phase III of the trial took place, the bulbs of the vaccine candidate and the rest of the necessary inputs to undertake this process.
After the opening of the codes, on June 21, the team of researchers from each site informed the volunteers vaccinated with placebo the day and time they should attend to administer the vaccine candidate, which shows the commitment of the promoting center with the immunization of these subjects, he stressed.
The doctor assured that, even at this stage, the medical follow-up of these people will continue in the event of any eventuality and concern, as they constitute the responsibility of the study until the application of the last dose with the short schedule of zero-14-28 days between one and other. He recognized the participation of the 48,290 phase III volunteers, and in particular, that of the placebos for their altruistic contribution to the final result: a drug with which the immunized person reduces the probability of developing COVID by 92.28% -19 symptomatic compared to who is not, and therefore reduces the risk of death.
This Monday, Miguel Díaz-Canel, First Secretary of the Central Committee of the Party and President of the Republic, congratulated the CIGB scientists for the effectiveness of Abdala, higher than the 50% recommended by the World Health Organization for an anti-SARS vaccine -Cov-2.
According to information published by ACN, the president also highlighted the loyalty of the creators of the vaccine candidate to the founding thought of Commander in Chief Fidel Castro in relation to the development of Cuban biotechnology and the improvement ideas proposed by Army General Raúl Castro from going from a budgeted model to a business one.
In a short time Abdala, composed of the receptor binding domain (RBD) of the virus protein adjuvanted in aluminum hydroxide, must have the emergency use authorization granted by the Center for State Control of Medicines, Equipment and Devices Doctors. While that happens, the inhabitants of the Hero City will attend, from today, happy and grateful to the vaccinations enabled in the health areas to receive a dose of love, effort and life.
Source: ACN
Views: 0
